Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
The latest drug development news and highlights from our FDA Performance Tracker
You may also be interested in...
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing
A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.
Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting
The Bausch & Lomb and Salix units are gaining sales momentum, execs said, while debt-reduction efforts remain ahead of schedule. They offered no excuses for a declining dermatology franchise, however.